Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate 40 mg in early amyotrophic lateral sclerosis (ALS)
2006-001688-49Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Glatiramer acetate 40 mg with Placebo (2 arms). Primary endpoint: Change in ALSFRS-R score (slope). Started Apr 2006; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2006-001688-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001688-49.